Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This is a monocentric, open label, randomized Phase II study in patients with brain
metastasis from melanoma, lung or breast cancer, who require treatment with high-dose
dexamethasone, as defined as a minimum of 8 mg daily based on the clinician judgment, for at
least three weeks, with or without radiation therapy. The aim is to investigate the metformin
efficacy in preventing the onset of glucocorticoid-induced diabetes and other metabolic
perturbations in patients with brain metastases from melanoma, lung or breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano